[November 09, 2017] |
|
Myelodysplastic Syndrome (MDS) Market Spotlight Report 2017 with 10 Year Forecasts - Research and Markets
The "Market
Spotlight: Myelodysplastic Syndrome (MDS)" report has been
added to Research and Markets' offering.
This Market Spotlight report covers the myelodysplastic syndrome market,
comprising key pipeline and marketed drugs, clinical trials, upcoming
and regulatory events, patent information, a 10-year disease prevalence
forecast, and licensing and acquisition deals, as well as presenting
drug-specific revenue forecasts.
Key Takeaways
-
The author estimates that in 2016, there were 356,800 incident cases
of myelodysplastic syndrome (MDS) worldwide, and forecasts that number
to increase to 390,800 incident cases by 2025.
-
The majority of industry-sponsored drugs in active clinical
development for MDS are in Phase II. Therapies in mid- and late-stage
development for MDS focus on a wide variety of targets. The majority
of the pipeline drugs in mid- to late-stage development for MDS are
administered via the oral route.
-
Approved drugs in the MDS space target DNA methyltransferase, BCR-ABL
fusion protein, KIT/c-KIT, platelet-derived growth factor receptor,
erythropoietin receptor, angiogenesis,and E3 ubiquitin ligase. The
majority of approved therapies are administered via the intravenous
route; however, a few products are available in oral and subcutaneous
formulations.
-
High-impact upcoming events for drugs in the MDS space include topline
Phase III and Phase II trial results. There were 16 licensing and
asset acquisition activities involving MDS drugs during 2012-17, six
of which occurred in 2014. The largest deal during this period was the
$935m exclusive licensing agreement in 2014 between Geron Corporation
and Janssen Biotech to develop and commercialize Geron Corporation's
imetelstat (a telomerase inhibitor) globally for oncology, including
hematologic malignancies, and other human therapeutics uses.
-
Revlimid's sales have ranked highest in the MDS space during 2012-16
and are forecasted to remain the highest during the forecast period
(2017-22).
-
The clinical trials distribution across Phases I-IV indicates that the
majority of the drugs are in early and mid-phases of development, with
90% of trials in Phase I-II, and only 10% in Phase III-IV.
-
The US has a substantial lead in the number of MDS clinical trials
globally. France leads the major EU markets, while Japan has the top
spot in Asia.
-
Celgene has the highest number of completed clinical trials for MDS.
The company has also had the highest number of Phase II and Phase III
clinical trials for MDS, with a count of 83 and 12, respectively
Key Topics Covered:
1 Key Takeaways
2 Disease Background
3 Treatment
4 Epidemiology
5 Pipeline Drugs
6 Marketed Drugs
7 Key Upcoming Events
8 Licensing And Asset Acquisition Deals
9 Parent Patents
10 Revenue Opportunity
11 Clinical Trial Landscape
12 Bibliography
13 Appendix
For more information about this report visit https://www.researchandmarkets.com/research/znphkf/market_spotlight
View source version on businesswire.com: http://www.businesswire.com/news/home/20171109005630/en/
[ Back To TMCnet.com's Homepage ]
|